Vytrus Biotech Statistics
Total Valuation
Vytrus Biotech has a market cap or net worth of EUR 98.94 million. The enterprise value is 95.98 million.
| Market Cap | 98.94M |
| Enterprise Value | 95.98M |
Important Dates
The next estimated earnings date is Thursday, March 25, 2027.
| Earnings Date | Mar 25, 2027 |
| Ex-Dividend Date | n/a |
Share Statistics
Vytrus Biotech has 7.52 million shares outstanding.
| Current Share Class | 7.52M |
| Shares Outstanding | 7.52M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 33.90% |
| Owned by Institutions (%) | 15.24% |
| Float | 3.77M |
Valuation Ratios
The trailing PE ratio is 24.53 and the forward PE ratio is 23.88.
| PE Ratio | 24.53 |
| Forward PE | 23.88 |
| PS Ratio | 9.90 |
| PB Ratio | 7.61 |
| P/TBV Ratio | 13.03 |
| P/FCF Ratio | 33.22 |
| P/OCF Ratio | 20.93 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.93, with an EV/FCF ratio of 32.22.
| EV / Earnings | 23.80 |
| EV / Sales | 9.60 |
| EV / EBITDA | 19.93 |
| EV / EBIT | 21.17 |
| EV / FCF | 32.22 |
Financial Position
The company has a current ratio of 3.42, with a Debt / Equity ratio of 0.08.
| Current Ratio | 3.42 |
| Quick Ratio | 3.09 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | 0.20 |
| Debt / FCF | 0.33 |
| Interest Coverage | 60.39 |
Financial Efficiency
Return on equity (ROE) is 36.82% and return on invested capital (ROIC) is 40.37%.
| Return on Equity (ROE) | 36.82% |
| Return on Assets (ROA) | 18.44% |
| Return on Invested Capital (ROIC) | 40.37% |
| Return on Capital Employed (ROCE) | 28.93% |
| Weighted Average Cost of Capital (WACC) | 3.91% |
| Revenue Per Employee | 212,702 |
| Profits Per Employee | 85,806 |
| Employee Count | 47 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 1.58 |
Taxes
In the past 12 months, Vytrus Biotech has paid 476,768 in taxes.
| Income Tax | 476,768 |
| Effective Tax Rate | 10.57% |
Stock Price Statistics
The stock price has increased by +64.38% in the last 52 weeks. The beta is -0.07, so Vytrus Biotech's price volatility has been lower than the market average.
| Beta (5Y) | -0.07 |
| 52-Week Price Change | +64.38% |
| 50-Day Moving Average | 15.34 |
| 200-Day Moving Average | 15.98 |
| Relative Strength Index (RSI) | 52.21 |
| Average Volume (20 Days) | 4,434 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Vytrus Biotech had revenue of EUR 10.00 million and earned 4.03 million in profits. Earnings per share was 0.54.
| Revenue | 10.00M |
| Gross Profit | 9.10M |
| Operating Income | 4.53M |
| Pretax Income | 4.51M |
| Net Income | 4.03M |
| EBITDA | 4.82M |
| EBIT | 4.53M |
| Earnings Per Share (EPS) | 0.54 |
Balance Sheet
The company has 3.95 million in cash and 987,122 in debt, with a net cash position of 2.96 million or 0.39 per share.
| Cash & Cash Equivalents | 3.95M |
| Total Debt | 987,122 |
| Net Cash | 2.96M |
| Net Cash Per Share | 0.39 |
| Equity (Book Value) | 13.00M |
| Book Value Per Share | 1.73 |
| Working Capital | 4.59M |
Cash Flow
In the last 12 months, operating cash flow was 4.73 million and capital expenditures -1.75 million, giving a free cash flow of 2.98 million.
| Operating Cash Flow | 4.73M |
| Capital Expenditures | -1.75M |
| Depreciation & Amortization | 281,992 |
| Net Borrowing | -596,773 |
| Free Cash Flow | 2.98M |
| FCF Per Share | 0.40 |
Margins
Gross margin is 91.06%, with operating and profit margins of 45.35% and 40.34%.
| Gross Margin | 91.06% |
| Operating Margin | 45.35% |
| Pretax Margin | 45.11% |
| Profit Margin | 40.34% |
| EBITDA Margin | 48.17% |
| EBIT Margin | 45.35% |
| FCF Margin | 29.80% |
Dividends & Yields
Vytrus Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 4.08% |
| FCF Yield | 3.01% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Vytrus Biotech has an Altman Z-Score of 12.69 and a Piotroski F-Score of 8.
| Altman Z-Score | 12.69 |
| Piotroski F-Score | 8 |